Randomised trial of dopamine compared with hydrocortisone for the treatment of hypotensive very low birthweight infants

David Bourchier, Philip J Weston

Abstract
Aim—to compare the efficacy of hydrocortisone with dopamine for the treatment of hypotensive, very low birthweight (VLBW) infants.

Methods—Forty infants were randomly allocated to receive either hydrocortisone (n=21) or dopamine (n=19).

Results—All 19 infants randomised to dopamine responded; 17 of 21 (81%) did so in the hydrocortisone group. Three of the four non-responders in the hydrocortisone group had clinically significant left to right ductal shunting. The incidence of bronchopulmonary dysplasia, retinopathy of prematurity, intraventricular haemorrhage, necrotising enterocolitis, symptomatic patent ductus arteriosus, hyperglycaemia, sepsis (bacterial or fungal) or survival did not differ between groups. The adrenocorticotropic hormone (ACTH) stimulated plasma cortisol activity, either before or after treatment, did not differ between the two groups of infants. Although a significant difference in efficacy between dopamine and hydrocortisone was not noted (P = 0.108), there were four treatment failures in the hydrocortisone group, compared with none in the dopamine group.

Conclusion—Both hydrocortisone and dopamine are effective treatments for hypotension in very low birthweight infants. (Arch Dis Child 1997;76:F174–F178)

Keywords: hydrocortisone; dopamine; hypotension; very low birthweight; plasma cortisol

Hypotension in very low birthweight (VLBW) infants is associated with both intraventricular haemorrhage and poor neurodevelopmental outcome. The pathophysiological basis for the hypotension is poorly understood, although factors such as reduced plasma cortisol and ducal patency may be important.

In 1987 Wood et al showed that there was a significant increase in mean arterial pressure (MAP) during cortisol infusion in the preterm ovine fetus which was subsequently confirmed by Tangalakis et al and Stein et al. Two retrospective studies of preterm human babies have since reported a significant increase in blood pressure after treatment with corticosteroids. No significant adverse effects were reported, although one of the centres subsequently noted an increase in systemic Candida sp infections in a case–control series.

Other studies have shown that volume expansion is less effective than the early use of dopamine in conditions where there is a poor correlation between blood pressure and blood volume.

Given the importance of hypotension as a problem among VLBW infants and the increasing use of corticosteroids in its management, we undertook a randomised trial to test the hypothesis that hydrocortisone is as effective as dopamine in treating hypotensive VLBW infants.

Method
During the period July 1993–June 1995, 40 hypotensive VLBW infants requiring inotropic support were enrolled in the study. Entry criteria were: (a) birthweight <1500 g; (b) age < 7 days; (c) absence of major congenital abnormality; (d) absence of shock (such as early onset sepsis or massive feto-maternal transfusion) requiring immediate inotropic or blood product support; (e) absence of a clinically significant patent ductus arteriosus (PDA) (LA:Ao >1.5 or diameter >1.5 mm) after the age of 3 days; (f) informed parental consent.

Hypotension was defined as a MAP of less than 25 mm Hg (birthweight 500–749 g), 30 mm Hg (birthweight 750–999 g), 35 mm Hg (birthweight 1000–1499 g) on two occasions 30 minutes apart. Infants were randomly allocated to receive either dopamine or hydrocortisone if they remained hypotensive following a single dose of colloid (10 ml/kg of 4% albumin) given intravenously over 20 minutes. If an infant responded to the initial dose of colloid but became hypotensive in the ensuing two hours they were also randomised as above. After randomisation (sealed envelopes containing random number table allocation) an ACTH stimulated cortisol test was performed using Synachten 35 mcg/kg intravenously. One ml of blood was collected before and 30 minutes after Synachten administration and stored at 4°C until assayed. Twenty four hours after stopping either hydrocortisone or dopamine treatment the ACTH stimulated cortisol test was repeated. Plasma cortisol was measured using a fluorometric enzyme immunoassay (Baxter Diagnostics) with interassay and intra-assay coefficients of variation of 6.8% and 5%, respectively, and a sensitivity of 8.5 nmol/l. Cross reaction for naturally occurring adrenal steroids was less than 3% except for 11-deoxycorticisol at 6.8%.
Dopamine was infused at an initial dose of 5 mcg/kg/minute, increasing stepwise to a maximum dose of 20 mcg/kg/minute if necessary. If hypotension persisted a noradrenaline infusion (0.05–0.5 mcg/kg/minute) was added. Once normotension had been maintained for 24 hours, the inotropes were reduced over a 24–48 hour period, as tolerated. Infants in the hydrocortisone group received the initial two doses of hydrocortisone (2.5 mg/kg) intravenously 4 hours apart. Subsequent doses were given 6 hourly for the remainder of the treatment period. The initial dose (2.5 mg/kg) was continued for 48 hours, followed by 1.25 mg/kg for 48 hours, then 0.625 mg/kg for a further 48 hours before stopping treatment. If, following a reduction in dose, hypotension recurred, the dose was increased to that previously administered for another 24 hours before attempting further reduction. Persisting hypotension after the first dose of hydrocortisone was managed by a further dose of colloid. If hypotension continued or developed after the second dose of hydrocortisone (before dose reduction), this was judged a treatment failure and the infant was prescribed dopamine. The dose of hydrocortisone was that used in our unit in the treatment of refractory hypoglycaemia and which had been observed to raise blood pressure. The aim of treatment was to maintain the MAP above the hypotensive limits described before. This was the target MAP.

Heart rate, MAP, inspired oxygen concentration and amount of supplementary fluid (colloid, blood products) were recorded at 0, 2, 4, 8, 12, 18, 24, 30, and 36 hours from start of treatment, then 12 hourly until study completion at 168 hours. Serum sodium, potassium, and creatinine were measured 12 hourly, together with a blood and urinalysis for glucose. Fluid intake and urine output were calculated daily in ml/kg/hour. The infants were nursed in a thermoneutral environment and received 60 to 180 ml/kg/day of parenteral nutrition, depending on postnatal age and serum sodium. An echocardiogram, including colour and Doppler studies, was performed on day 3 (or earlier if hypotension persisted despite initiation of treatment) using an Advanced Technology Laboratories Ultramark 9 scanner with 5 MHz transducer.

The primary outcome measure was persisting hypotension despite treatment. Secondary outcome measures were the correlation between plasma cortisol concentrations and response to treatment and the effect of treatment on these values. The following clinical outcomes were also recorded: survival; intraventricular haemorrhage (graded 1 to 4, as per Papile); bronchopulmonary dysplasia (O2 requirement at 36 weeks corrected gestation); retinopathy of prematurity; sepsis (positive blood cultures with signs of systemic illness) from the onset of treatment until 14 days (bacterial) or 42 days (fungal) after it had been stopped.

Pre-study power analysis showed that to detect a 20% failure rate in one group compared with the other (α = 0.05, β = 0.2), 19 infants would be needed in each group. Parametric data were analysed using Analysis of Variance (ANOVA) with repeated measures for blood pressure results, and t tests for other single comparisons. The χ² and Fisher’s exact tests were used to analyse differences in proportions, Mann-Whitney U tests for non-parametric comparisons, and Pearson’s correlation coefficients were used to determine correlations between cortisol values and inotropic support. In all cases an α-value of 0.05 was used to determine significance.

The study was approved by the Waikato Hospital Ethics Committee.

**Results**

During the two years of study, 145 infants with a birthweight <1500 g were admitted to the Waikato Hospital Newborn Unit. Fifty six (38.6%) were hypotensive in the first week of life and potentially eligible for the study. Three were shocked, requiring immediate blood product and inotropic support; consent was declined in one and there were 13 enrolment failures (the physician omitted to approach parents). The remaining 39 were enrolled in the study, plus one infant from Christchurch Hospital (total number 40).

Nineteen infants were randomised to the dopamine group and 21 to the hydrocortisone group. Patient characteristics and details at onset of treatment were similar for both groups (table 1), except that the dopamine group were of larger birthweight than the other group. The median deficit between the MAP at study entry and the target MAP was 3 mm Hg (range 1–12) for the dopamine group, and 5 mm Hg (range 0–12) for the hydrocortisone group.

In both groups blood pressure improved. The averaged MAPs for each group rapidly reached and remained above the target level throughout the study period (fig 1). ANOVA with repeated measures confirmed a difference between the two groups (P < 0.05), with the hydrocortisone group having a consistently higher MAP from 48 hours onwards. This difference most probably reflects the variation in weaning schedules. The hydrocortisone group was weaned slowly by fixed decrements over 144 hours; the dopamine group was weaned as rapidly as the MAP would allow. This slower weaning of the hydrocortisone group meant that three of the infants became hypertensive (MAPs of 55, 55, 45 mm Hg at birthweights of 668, 805, and 679 g, respectively) and their treatment was curtailed at 48, 72, and 120 hours.

**Table 1** Patient characteristics (mean(SD))

<table>
<thead>
<tr>
<th></th>
<th>Dopamine (n=19)</th>
<th>Hydrocortisone (n=21)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Birthweight (g)</td>
<td>1043 (184)</td>
<td>923 (188)</td>
<td>0.048</td>
</tr>
<tr>
<td>Gestation (weeks)</td>
<td>27.5 (1.6)</td>
<td>26.6 (2.1)</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>M/F</td>
<td>9:10</td>
<td>9:12</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Age at onset of treatment (hours)</td>
<td>15.1 (10.1)</td>
<td>11.4 (13.0)</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Respiratory distress syndrome (n=)</td>
<td>17</td>
<td>18</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Surfactant (n=)</td>
<td>18</td>
<td>21</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Maternal steroids (n=)</td>
<td>4</td>
<td>9</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Colloid/blood given in 12 hours before treatment (ml/kg)</td>
<td>15.1 (10.5)</td>
<td>17.4 (9.1)</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Median MAP deficit at entry (mm Hg)</td>
<td>3</td>
<td>5</td>
<td>&gt;0.05</td>
</tr>
</tbody>
</table>
The age at post-treatment sampling was different because the dopamine group tended to reach the end of treatment before the hydrocortisone group.

The pre-treatment cortisol concentrations were analysed in the dopamine group to determine any correlation between them and maximum inotropic requirement. There was no relation between the pre-treatment basal cortisol values and the subsequent maximum dopamine dose ($r=0.13, P>0.05$), nor between pre-treatment cortisol increment and maximum dopamine dose ($r=0.38, P>0.05$).

There was no difference in outcome for all variables measured (table 3). The hydrocortisone group did not show an increased rate of sepsis. There were four infants in this group who developed sepsis, all with coagulase negative staphylococci. In the dopamine group there were six cases, of which three had coagulase negative staphylococci, two group B streptococci, and one Enterococcus faecalis. No episode of fungal sepsis was noted in either group in the study period. An insulin infusion for hyperglycaemia was required in five of the dopamine group and in seven of the hydrocortisone group (not significantly different).

**Discussion**

Hypotension in VLBW infants is a recognised risk factor in the pathogenesis of intraventricular haemorrhage and is known independently to affect neurodevelopmental outcome at 24 months. Although the aetiology of the hypotension in these infants is poorly understood, evidence suggests a pivotal role for corticosteroids in mediating the effects of endogenous catecholamines. This phenomenon could be explained by either a direct effect of the corticosteroids on the myocardium or vessel wall or, indirectly, via an increase in adrenergic receptor numbers. Several clinical studies provide further evidence for the importance of corticosteroids. Firstly, infants born to mothers who received antenatal corticosteroids are less likely to become hypotensive than those born to mothers who did not. Secondly, Scott et al reported that hypotensive infants requiring inotropic support had lower plasma cortisol values than those who remained normotensive. Furthermore, two retrospective clinical studies have reported a significant improvement in blood pressure in infants with refractory hypotension following corticosteroid treatment. In one of these studies, pre-treatment plasma cortisol values were measured and found to be low.

We found ACTH stimulated plasma cortisol concentrations similar to those reported by Thomas, with basal values significantly higher than those reported by Scott, Helbock, and Saedi. The variation in reported plasma cortisol reflects the different methods of assay (radioimmunoassay, or fluorescence immunoassay) and the differences in the study populations where gestation, postnatal age, severity of illness and time of sampling all differed. The pre-treatment basal plasma cortisol did not predict either the likelihood of successful treatment in the hydrocortisone group or the dose range 17–265 hours). No infant required a mean duration of treatment of 90.6 hours from 5–20 mcg/kg/minute (median = 10) with a mean duration of treatment of 90.6 hours (range 17–265 hours). No infant required a noradrenaline infusion.

Before treatment there was no difference between the groups in cortisol concentrations either before or after ACTH, and the incremental change on stimulation was also similar (table 2). No significant intergroup difference was noted at 0 or 30 minutes after treatment.

There was no difference in this time period in either the number of infants receiving additional (colloid or blood product) fluid support or the amount received. Seventeen infants in the dopamine group received 15.1 (SD 10.5) ml/kg in the 12 hours before treatment and 66.5 (30.2) ml/kg during treatment (n=18). By comparison, in the hydrocortisone group 19 infants received 17.4 (9.1) ml/kg before treatment and 57.3 (48.4) ml/kg during treatment (n=19).

The maximum dose of dopamine ranged from 5–20 mcg/kg/minute (median = 10) with a mean duration of treatment of 90.6 hours (range 17–265 hours). No infant required a noradrenaline infusion.

Before treatment there was no difference between the groups in cortisol concentrations either before or after ACTH, and the incremental change on stimulation was also similar (table 2). No significant intergroup difference was noted at 0 or 30 minutes after treatment.

**Figure 1** Blood pressure changes over time. Average MAPs at each recording time are shown for both groups as increments above target MAPs (as target MAP varied with birthweight). Data from the four infants who failed in the hydrocortisone group are excluded from the time they stopped receiving hydrocortisone. Vertical bars indicate standard deviations (SD).

**Figure 2** Proportion of infants with MAP above target value in first 12 hours after treatment.
Table 2 ACTH stimulated plasma cortisols before and after treatment (mean(SD))

<table>
<thead>
<tr>
<th></th>
<th>Before</th>
<th>After</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hydrocortisone (n=21)</td>
<td>Hydrocortisone (n=14)</td>
<td>Hydrocortisone (n=17)</td>
</tr>
<tr>
<td>Age (hours)</td>
<td>11.0 (12.8)</td>
<td>14.6 (10.3)</td>
</tr>
<tr>
<td>Plasma cortisol (nmol/l)</td>
<td>414.8 (394.9)</td>
<td>411.9 (262.1)</td>
</tr>
<tr>
<td>0 mins</td>
<td>580.5 (455.4)</td>
<td>657.8 (448.4)</td>
</tr>
<tr>
<td>Increment</td>
<td>166.8 (142.4)</td>
<td>215.7 (314.3)</td>
</tr>
</tbody>
</table>

* = P < 0.05, Mann-Whitney U test.

Table 3 Outcome

<table>
<thead>
<tr>
<th></th>
<th>Dopamine</th>
<th>Hydrocortisone</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>No (%)</td>
<td>No (%)</td>
<td>P value</td>
<td></td>
</tr>
<tr>
<td>Treatment success</td>
<td>19 (100)</td>
<td>17 (81)</td>
<td>0.108</td>
</tr>
<tr>
<td>Survival</td>
<td>18 (95)</td>
<td>19 (90)</td>
<td>&gt; 0.05</td>
</tr>
<tr>
<td>Bronchopulmonary dysplasia</td>
<td>2/18 (11)</td>
<td>5/19 (26)</td>
<td>&gt; 0.05</td>
</tr>
<tr>
<td>Retinopathy of prematurity (stage 2-4)</td>
<td>3/18 (17)</td>
<td>4/19 (21)</td>
<td>&gt; 0.05</td>
</tr>
<tr>
<td>Intraventricular haemorrhage (grades 2-4)</td>
<td>3/19 (16)</td>
<td>5/21 (24)</td>
<td>&gt; 0.05</td>
</tr>
<tr>
<td>Necrotising enterocolitis</td>
<td>1/19 (5)</td>
<td>4/21 (19)</td>
<td>&gt; 0.05</td>
</tr>
<tr>
<td>Symptomatic patent ductus arteriosus</td>
<td>9/19 (47)</td>
<td>8/21 (38)</td>
<td>&gt; 0.05</td>
</tr>
<tr>
<td>Insulin requirement</td>
<td>5/19 (26)</td>
<td>7/21 (33)</td>
<td>&gt; 0.05</td>
</tr>
<tr>
<td>Sepsis</td>
<td>6/19 (32)</td>
<td>4/21 (19)</td>
<td>&gt; 0.05</td>
</tr>
</tbody>
</table>

The mechanism by which corticosteroids improve blood pressure is equally poorly understood, with evidence coming from both in vivo and in vitro animal studies and indirectly from patients with corticosteroid excess who become hypertensive. Proposed mechanisms of action can be divided into two broad groups: those which increase synthesis of a specific protein or those which enhance vascular sensitivity to catecholamines. Given the rapid onset of action of the hydrocortisone in this study, the latter mechanism seems to have been the more important, at least initially. Kalsner postulated that the enhanced vascular sensitivity to catecholamines was due to inhibition of catechol-O-methyltransferase metabolism of catecholamines, while Bassett et al demonstrated that inhibition of noradrenaline uptake at neuronal and extraneuronal sites increased myocardial sensitivity to noradrenaline following exposure to glucocorticoid or ACTH. Tangalakis et al., however, were unable to confirm an increase in vascular sensitivity to noradrenaline in fetal sheep during a cortisol infusion, despite a significant increase in blood pressure. Actions mediated by alterations in protein synthesis include an increase in human polymorph β-adrenergic receptor number by up to 40% in a four hour period after administration of cortisone acetate. Mano et al noted a 70% increase in rat pulmonary β-adrenergic receptor density after nine days of hydrocortisone, with similar phenomena reported in rabbits but not sheep. The increase in β-adrenergic receptors in the peripheral blood is mirrored by similar increases in the myocardium. In addition to increasing β-adrenergic receptor numbers, corticosteroids enhance adenylate cyclase activity following agonist stimulation via enhanced gene transcription. Otten et al have shown that two of the key enzymes in catecholamine synthesis—namely, tyrosine hydroxylase and dopamine-B-hydroxylase—are induced by corticosteroids in the presence of other factors. Similarly, angiotensin 2 (type 1) receptor gene expression in fetal lamb cardiac tissue is increased following cortisol infusion.

Potential disadvantages of corticosteroids include hyperglycaemia, adrenal suppression, and increased infection risk. Surprisingly, we noted no evidence of blood glucose disturbance despite using a dose of hydrocortisone which we have found to be effective in the treatment of refractory hypoglycaemia. Although the plasma cortisol response to ACTH after treatment was less in the hydrocortisone group, there was no difference between the basal plasma cortisols. This does not represent a significant degree of adrenal suppression. Unlike Botas et al, we found no increase in bacterial or fungal sepsis. Other randomised trials of postnatal corticosteroid treatment in VLBW infants have also failed to show an increased incidence of such infections.

Current management of the hypotensive VLBW infant includes colloid, inotropes (especially dopamine) and corticosteroids in refractory cases. Given that blood pressure is poorly correlated with blood volume and that fluid overload may be important in the aetiology of ducal patency and bronchopulmonary dysplasia, colloid should be used judiciously. Despite the effectiveness of dopamine, there are concerns regarding its potential to increase both pulmonary and renal vascular resistances, and to diminish cardiac output. A recent concern is the potential to increase bacterial and fungal sepsis. Hydrocortisone was as effective as dopamine, which is the most commonly used inotrope in such infants. The small sample size and magnitude of effect sought may have hidden less clinically significant, but potentially important, differences. Hydrocortisone was easily administered as a slow, parenteral bolus, thus obviating the need for a dedicated intravenous line and eliminating the risk of an inadvertent inotrope bolus. Dopamine, however, had the advantage of being more easily titrated according to response.
In summary, both dopamine and hydrocortisone are effective treatments for hypotension in very low birthweight infants. Future studies evaluating different corticosteroids and tapering regimens seem justified.

We thank Drs P Heron, T Watson, and B Darlow for their clinical contributions.

Randomised trial of dopamine compared with hydrocortisone for the treatment of hypotensive very low birthweight infants

David Bourchier and Philip J Weston

Arch Dis Child Fetal Neonatal Ed 1997 76: F174-F178
doi: 10.1136/fn.76.3.F174

Updated information and services can be found at:
http://fn.bmj.com/content/76/3/F174

These include:

References
This article cites 37 articles, 15 of which you can access for free at:
http://fn.bmj.com/content/76/3/F174#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Drugs: CNS (not psychiatric) (191)
Bronchopulmonary dysplasia (95)
Clinical trials (epidemiology) (252)
Congenital heart disease (152)
Diabetes (128)
Eye Diseases (86)
Metabolic disorders (291)
Ophthalmology (120)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/